Nuvation Bio Surges On Ibtrozi Momentum And B. Riley Buy Rating [Seeking Alpha]
Nuvation Bio Inc. Class A (NUVB)
Company Research
Source: Seeking Alpha
NUVB surged nearly 48% after B. Riley Securities initiated coverage with a Buy rating and $12 price target, citing robust Ibtrozi launch momentum. To meet 2026 revenue targets, NUVB must accelerate patient adoption for Ibtrozi, with international expansion and label enhancements supporting growth. Valuation is now elevated, reflecting high expectations; future performance depends on sustained patient uptake and meeting quarterly revenue milestones. PonyWang/E+ via Getty Images Thesis Nuvation Bio Inc. ( NUVB ) reported a pretty solid array of 3Q25 figures . GAAP EPS came in at a loss of just $0.16, beating expectations by $0.01, while total revenue came in at $13.12 million, also surpassing estimates by $6.26 This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own
Show less
Read more
Impact Snapshot
Event Time:
NUVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVB alerts
High impacting Nuvation Bio Inc. Class A news events
Weekly update
A roundup of the hottest topics
NUVB
News
- Nuvation Bio (NUVB) Bounces Back 12% on Impressive Clinical Trial Result [Yahoo! Finance]Yahoo! Finance
- Lenz Therapeutics: A Close Look [Seeking Alpha]Seeking Alpha
- Nuvation Bio Inc. (NUVB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript [Seeking Alpha]Seeking Alpha
- Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-OncologyBusiness Wire
- Nuvation Bio (NYSE:NUVB) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
NUVB
Earnings
- 11/3/25 - Beat
NUVB
Sec Filings
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- 11/26/25 - Form 4
- NUVB's page on the SEC website